Ashwagandha Supplement

## What it is Ashwagandha is the dried root extract of Withania somnifera, a small woody shrub in the nightshade family native to India, the Middle East, and parts of Africa. The Sanskrit name translates roughly to 'smell of the horse', a reference to both the root's odor and the traditional claim that it confers stamina. It is one of the most heavily used herbs in Ayurvedic medicine, with documented use stretching back roughly 3,000 years to the Charaka Samhita. The modern supplement market is dominated by two patented standardized extracts. KSM-66, manufactured by Ixoreal Biomed since 2009, is a full-spectrum root extract standardized to roughly 5% withanolides by HPLC and is the extract used in the largest body of contemporary RCTs. Sensoril, manufactured by Natreon, is a root-and-leaf extract standardized to a higher 10% withanolide content and shows up most often in older trials. Generic ashwagandha root powder sits below both on standardization but above on price; it works, but the dose-response data lives in the standardized extract literature. Legally it is a dietary supplement in most jurisdictions. Denmark restricts sales after a 2020 risk assessment cited concerns about thyroid and reproductive effects, and Sweden and Finland have followed with similar advisories. WADA does not list it. Most of the marketing copy attached to ashwagandha leans hard on bro-science framing for testosterone and muscle gain; the actual evidence base is heaviest in stress, anxiety, and sleep, with smaller and less consistent signals on the hormonal endpoints. ## Mechanism of action The active constituents are a family of steroidal lactones called withanolides, of which withaferin A and withanolide A are the best characterized. Withanolides modulate the hypothalamic-pituitary-adrenal axis, attenuating cortisol secretion in response to perceived stress. The mechanism is not fully resolved but appears to involve GABAergic potentiation, inhibition of NF-kB signaling, and direct effects on glucocorticoid receptor expression. Acute single-dose studies show modest effects; the cortisol curve really moves over 4 to 8 weeks of consistent dosing, which is the timescale most RCTs report. Withaferin A has a preclinical half-life on the order of 7 to 10 hours in rodents. Human pharmacokinetic data on the full extract is limited because the standardized products are mixtures rather than single molecules, and analytical methods for the full withanolide profile are inconsistent across labs. The functional half-life of the standardized extracts in clinical use appears to be long enough to support once- or twice-daily dosing with stable steady-state effects after 2 to 4 weeks. Beyond the HPA axis, ashwagandha modulates thyroid output. Multiple small trials have shown small increases in T3 and T4 with corresponding decreases in TSH at 600 mg/day for 8 weeks. The effect is large enough to be clinically meaningful in subclinical hypothyroidism and large enough to interact with levothyroxine dosing in treated hypothyroid patients. There is no convincing evidence of direct thyroid receptor binding; the proposed mechanism is HPA-mediated downstream of stress reduction. ## Evidence base by outcome ### Cortisol and subjective stress This is the cleanest part of the evidence base. Across 7 to 8 RCTs in chronically stressed adults, KSM-66 or Sensoril at 300 to 600 mg/day for 60 days produced morning serum cortisol reductions of roughly 20 to 30% versus placebo. Salve 2019 (n=60, 600 mg/day, 8 weeks) reported a 27.9% cortisol reduction versus 7.9% on placebo (p less than .001). Lopresti 2019 (n=60, 240 mg/day Shoden extract, 60 days) reported a 23% morning cortisol drop versus placebo. Subjective stress scores on DASS-21 and PSS scales tracked the cortisol changes consistently across these trials with effect sizes of roughly 0.5 to 0.8 standard deviations. ### Anxiety A 2014 systematic review (Pratte) and a 2019 meta-analysis (Chandrasekhar) both concluded that standardized ashwagandha extract produces clinically meaningful reductions in HAM-A and BAI scores in adults with generalized anxiety symptoms, with effects on the order of 5 to 8 points on HAM-A. The trials are mostly small (n=40 to 80), short (4 to 12 weeks), and conducted in India by groups with industry funding, which warrants caution. The effect direction is consistent across trials but the magnitude estimate is wide. ### Sleep Five small RCTs in adults with insomnia symptoms have reported modest improvements in PSQI and sleep onset latency at 300 to 600 mg/day for 6 to 8 weeks. Effects are smaller than dedicated sleep agents and on the order of a 1 to 2 point PSQI improvement. The effect is most plausibly downstream of cortisol normalization rather than direct sedation, which fits the observation that benefits build over weeks rather than appearing acutely. ### Strength and testosterone This is where the evidence is weakest and the marketing is loudest. Wankhede 2015 (n=57 trained men, 600 mg/day, 8 weeks) reported 5 to 8% greater 1RM gains on bench and squat in the treatment arm versus placebo, alongside roughly a 15% testosterone increase. Lopresti 2019 (n=60 stressed men, 240 mg/day, 8 weeks) reported a 14.7% testosterone increase versus 5.9% on placebo. The trials are small, the populations are skewed toward stressed or subfertile men with low baselines, and replication in healthy young men with normal baseline testosterone is thin. Treat the strength and testosterone effects as plausible but secondary, not as the primary reason to take the herb. ### Thyroid hormones Sharma 2018 (n=50, 600 mg/day, 8 weeks in subclinical hypothyroidism) reported T3 increases of 41% and T4 of 19.6% with TSH falling 17.5%. The signal is small in absolute hormone units but clinically relevant in subclinical hypothyroidism and clinically problematic for levothyroxine users. ## Dosage and protocols The standard dose is 300 to 600 mg/day of a standardized extract (KSM-66, Sensoril, or Shoden), taken once daily with food or split morning and evening. Most RCTs run 8 to 12 weeks of continuous dosing. Generic root powder doses sit closer to 3 to 6 g/day to approximate the withanolide content, but the concentration varies enough between batches that the clinical signal is muddier. No formal cycling protocol exists. The longest published RCT with safety follow-up runs to 12 weeks. Long-term safety beyond that is inferred from traditional Ayurvedic use rather than measured. A defensible heuristic is to run 8 to 12 week blocks with 2 to 4 week washouts, particularly if you take it primarily for an acute stressor that resolves. Dose-response data above 600 mg/day is sparse. A few trials have used 1,200 mg/day with broadly similar effects, suggesting a plateau around the standard 600 mg dose. Doses below 300 mg/day in standardized extracts do not consistently move cortisol and probably represent a sub-clinical dose for the primary indication. ## Side effects and safety GI side effects are the most common adverse event in trials, reported by roughly 5 to 10% of users at 600 mg/day. Drowsiness and headache appear at lower rates. The Danish risk assessment that triggered the regional restrictions in 2020 cited theoretical concerns about reproductive toxicity (preclinical signals) and thyroid effects rather than direct human harm signals. Contraindications include pregnancy (preclinical abortifacient signal at high doses), autoimmune disease (theoretical immune stimulation, though not clearly demonstrated in humans), hyperthyroidism (the thyroid signal would be additive), and concurrent benzodiazepine use (additive CNS depression). Levothyroxine users should not start ashwagandha without monitoring TSH at 4 and 8 weeks; the dose may need reduction. Long-term safety beyond 12 weeks remains underdocumented in modern RCT formats. Hepatotoxicity case reports surfaced from 2020 onward, with roughly a dozen published cases of hepatocellular liver injury attributed to ashwagandha, most of which resolved on discontinuation. The absolute incidence is low but real, and it is the strongest argument for not running it indefinitely without periodic liver function checks. ## Stack interactions and timing Ashwagandha pairs naturally with magnesium glycinate and melatonin in evening sleep stacks, and the components target different mechanisms (HPA, NMDA modulation, circadian phase) without obvious antagonism. Pairing with caffeine is fine and is the standard daytime layout for users seeking the anxiolytic effect without sedation. Direct interactions to avoid: benzodiazepines and other GABAergic sedatives (additive sedation), levothyroxine (thyroid axis interaction), immunosuppressants (theoretical antagonism), and SSRIs at the moment of initiation (mild serotonergic signal in preclinical work, though not a clinical concern in published trials). It does not interact meaningfully with food, and morning or evening dosing produces similar steady-state effects. ## Practical notes Buy a standardized extract. KSM-66 and Sensoril are the two with the most clinical data and the most consistent withanolide content. Generic root powders are cheaper but vary in withanolide concentration by an order of magnitude, which means the dose-response data does not transfer cleanly. Third-party testing for heavy metals is non-trivial: ashwagandha is grown in regions where soil contamination is a real concern, and reputable brands publish certificates of analysis on request. Expect 2 to 4 weeks before noticeable subjective changes. The cortisol effect builds slowly. If you have not noticed reduced morning anxiety or improved sleep latency by week 6 at 600 mg/day, additional dose escalation is unlikely to help. Stop and reassess. The most common error is treating ashwagandha as an acute anxiolytic, which it is not, and abandoning it after a week. Store in a cool, dry container away from sunlight. Withanolide content degrades on extended exposure to heat and humidity, which is one of the practical reasons cheap powders underperform standardized extracts even at matched milligram doses.